Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor
Authors: Andrzej P. Kudelka
Apichai Vasuratna
Creigton L. Edwards
Kristan Augustine
Mongkol Benjapibal
Claire F. Verschraegen
John J. Kavanagh
University of Texas MD Anderson Cancer Center
Chulalongkorn University
Mahidol University
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jan-1998
Citation: Anti-Cancer Drugs. Vol.9, No.7 (1998), 621-623
Abstract: A 19-year-old woman with refractory juvenile granulosa cell tumors had persistent disease after PVB (cisplatin, vinblastino and bleomycin) and multiple high doses of ICE (ifosfamide, carboplatin and etoposide) with peripheral stem cell support. She achieved stable disease for 4 months with low dose intensity gemcitabine of 500 mg/m2/week. The planned dose had been 1250 mg/m2/week. The dose intensity was limited by myelosuppression especially thrombocytopenia. The use of thrombopoietic, in addition to erythropoietic and myelopoletic, agents may permit higher dose intensity of gemcitabine after bone marrow ablative therapy with resulting greater anti tumor activity.
ISSN: 09594973
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.